Int J Angiol 2015; 24(02): 075-080
DOI: 10.1055/s-0034-1396413
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Role of Advanced Glycation End Products and Its Receptors in the Pathogenesis of Cigarette Smoke-Induced Cardiovascular Disease

Kailash Prasad
1   Department of Physiology, College of Medicine, University of Saskatchewan, Saskatoon, Canada
,
Indu Dhar
2   Department of Pharmacology, College of Medicine, University of Saskatchewan, Saskatoon, Canada
,
Gudrun Caspar-Bell
3   Department of Medicine, Royal University Hospital, College of Medicine, University of Saskatchewan, Saskatoon, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
12 December 2014 (online)

Abstract

The interaction of advanced glycation end products (AGEs) with its cell-bound receptor RAGE increases gene expression and release of proinflammatory cytokines and increase generation of reactive oxygen species (ROS). Circulating receptors, soluble RAGE (sRAGE), and endosecretory RAGE (esRAGE) by binding with RAGE ligands have protective effects against AGE–RAGE interaction. Cigarette smoking is a risk factor for coronary artery disease, stroke, and peripheral vascular disease. This article reviews; if the AGE–RAGE axis is involved in the cigarette smoke-induced cardiovascular diseases. There are various sources of AGEs in smokers including, gas/tar of cigarette, activation of macrophages and polymorphonuclear leukocytes, uncoupling of endothelial isoform of nitric oxide synthase (eNOS) and xanthine oxidase. The levels of AGEs are elevated in smokers. Serum levels of sRAGE have been reported to be reduced, elevated, or unchanged in smokers. Mostly the levels are reduced. There is one article which shows an elevation of levels of sRAGE in smokers. Serum levels of esRAGE are unaltered in smokers. Mechanism of AGE–RAGE-induced atherosclerosis has been discussed. Atherosclerosis leads to the cardiovascular diseases. It has been suggested that ratio of AGE/sRAGE or AGE/esRAGE is useful in determining the deleterious effects of AGE–RAGE interaction in smokers. sRAGE alone is not a good marker for smoke-induced cardiovascular disease. In conclusion cigarette smoke induces formation of AGEs and reduces sRAGE resulting in the development of atherosclerosis and related coronary heart disease, stroke, and peripheral vascular disease. Ratio of AGEs/sRAGE is a better marker for cardiovascular disease than AGEs or sRAGE alone in smokers.

 
  • References

  • 1 Ockene IS, Miller NH ; American Heart Association Task Force on Risk Reduction. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. Circulation 1997; 96 (9) 3243-3247
  • 2 Price JF, Mowbray PI, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J 1999; 20 (5) 344-353
  • 3 Black HR. Smoking and cardiovascular disease. In: Laragh JH, Brenner BM, , eds. Hypertension: Pathophysiology, Diagnosis and management. 2nd ed. New York, NY: Raven Press Ltd; 1995: 2621-2647
  • 4 Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004; 43 (10) 1731-1737
  • 5 Negri E, Franzosi MG, La Vecchia C, Santoro L, Nobili A, Tognoni G ; GISSI-EFRIM Investigators. Tar yield of cigarettes and risk of acute myocardial infarction. BMJ 1993; 306 (6892) 1567-1570
  • 6 Jonas MA, Oates JA, Ockene JK, Hennekens CH ; American Heart Association. Statement on smoking and cardiovascular disease for health care professionals. Circulation 1992; 86 (5) 1664-1669
  • 7 Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke: nearly as large as smoking. Circulation 2005; 111 (20) 2684-2698
  • 8 Herbert WH. Cigarette smoking and arteriographically demonstrable coronary artery disease. Chest 1975; 67 (1) 49-52
  • 9 Waters D, Lespérance J, Gladstone P , et al; CCAIT Study Group. Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. Circulation 1996; 94 (4) 614-621
  • 10 Office of the Surgeon General (US), Office on Smoking and Health (US). The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention. Circulation 2005; 111 (20) 2684-2698
  • 11 Benowitz NL. Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis 2003; 46 (1) 91-111
  • 12 U.S Department of Health and Human Services. The Health benefits of Smoking cessation: A Report of the Surgeon General, DHHS Publication No. (CDC) 90–8416. Rockville, MD: U.S Department of Health and Human Services, Public health Services, Centers for Disease Control and Prevention; 1990
  • 13 Prasad K. Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Circulation 1999; 99 (10) 1355-1362
  • 14 Prasad K, Lee P. Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism. Atherosclerosis 2007; 192 (2) 313-322
  • 15 Pryor WA, Stone K. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann N Y Acad Sci 1993; 686: 12-27 , discussion 27–28
  • 16 Smith CJ, Fischer TH. Particulate and vapor phase constituents of cigarette mainstream smoke and risk of myocardial infarction. Atherosclerosis 2001; 158 (2) 257-267
  • 17 Barua RS, Ambrose JA, Srivastava S, DeVoe MC, Eales-Reynolds LJ. Reactive oxygen species are involved in smoking-induced dysfunction of nitric oxide biosynthesis and upregulation of endothelial nitric oxide synthase: an in vitro demonstration in human coronary artery endothelial cells. Circulation 2003; 107 (18) 2342-2347
  • 18 Srivastava SK, Barua RS, Saha DC, Eales-Reynolds LJ, DeVoe MC, Ambrose JA. Endogenous free radical generating source are involved in smoking-mediated dysfunction of nitric oxide biosynthesis in human coronary artery endothelial cells: an in vitro demonstration. (abstr). J Am Coll Cardiol 2003; 41 (Suppl A) 306A
  • 19 Kayyali US, Budhiraja R, Pennella CM , et al. Upregulation of xanthine oxidase by tobacco smoke condensate in pulmonary endothelial cells. Toxicol Appl Pharmacol 2003; 188 (1) 59-68
  • 20 Guthikonda S, Sinkey C, Barenz T, Haynes WG. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation 2003; 107 (3) 416-421
  • 21 Kalra J, Chaudhary AK, Prasad K. Increased production of oxygen free radicals in cigarette smokers. Int J Exp Pathol 1991; 72 (1) 1-7
  • 22 Falcone C, Emanuele E, D'Angelo A , et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005; 25 (5) 1032-1037
  • 23 Lindsey JB, de Lemos JA, Cipollone F , et al. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care 2009; 32 (7) 1218-1220
  • 24 Hudson BI, Moon YP, Kalea AZ , et al. Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS). Atherosclerosis 2011; 216 (1) 192-198
  • 25 McNair ED, Wells CR, Qureshi AM , et al. Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients. Int J Angiol 2009; 18 (4) 187-192
  • 26 McNair ED, Wells CR, Mabood Qureshi A , et al. Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention. Clin Cardiol 2010; 33 (11) 678-685
  • 27 Basta G, Berti S, Cocci F , et al. Plasma N-epsilon-(carboxymethyl)lysine levels are associated with the extent of vessel injury after coronary arterial stenting. Coron Artery Dis 2008; 19 (5) 299-305
  • 28 Park L, Raman KG, Lee KJ , et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998; 4 (9) 1025-1031
  • 29 Sakaguchi T, Yan SF, Yan SD , et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003; 111 (7) 959-972
  • 30 Bucciarelli LG, Wendt T, Qu W , et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002; 106 (22) 2827-2835
  • 31 Prasad K. Soluble receptor for advanced glycation end products (sRAGE) and cardiovascular disease. Int J Angiol 2006; 15: 57-68
  • 32 Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000; 1498 (2-3) 99-111
  • 33 Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998; 37 (3) 586-600
  • 34 Tam XHL, Shiu SWM, Leng L, Bucala R, Betteridge DJ, Tan KCB. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes. Clin Sci (Lond) 2011; 120 (2) 81-89
  • 35 Yonekura H, Yamamoto Y, Sakurai S , et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370 (Pt 3) 1097-1109
  • 36 Koyama H, Shoji T, Yokoyama H , et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005; 25 (12) 2587-2593
  • 37 Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84 (5) 489-497
  • 38 Cerami C, Founds H, Nicholl I , et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A 1997; 94 (25) 13915-13920
  • 39 Nicholl ID, Bucala R. Advanced glycation endproducts and cigarette smoking. Cell Mol Biol (Noisy-le-grand) 1998; 44 (7) 1025-1033
  • 40 Radoi V, Lixandru D, Mohora M, Vîrgolici B. Advanced glycation end products in diabetes mellitus: mechanism of action and focused treatment. Proc Rom Acad, Series B. 2012; 1: 9-19
  • 41 Berg TJ, Snorgaard O, Faber J , et al. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care 1999; 22 (7) 1186-1190
  • 42 Nicholl ID, Stitt AW, Moore JE, Ritchie AJ, Archer DB, Bucala R. Increased levels of advanced glycation endproducts in the lenses and blood vessels of cigarette smokers. Mol Med 1998; 4 (9) 594-601
  • 43 Gopal P, Reynaert NL, Scheijen JL , et al. Association of plasma sRAGE, but not esRAGE with lung function impairment in COPD. Respir Res 2014; 15: 24
  • 44 Iwamoto H, Gao J, Pulkkinen V, Toljamo T, Nieminen P, Mazur W. Soluble receptor for advanced glycation end-products and progression of airway disease. BMC Pulm Med 2014; 14: 68
  • 45 Yokota C, Minematsu K, Tomii Y , et al. Low levels of plasma soluble receptor for advanced glycation end products are associated with severe leukoaraiosis in acute stroke patients. J Neurol Sci 2009; 287 (1-2) 41-44
  • 46 Biswas SK, Mudi SR, Mollah FH, Bierhaus A, Arslan MI. Serum soluble receptor for advanced glycation end products (sRAGE) is independently associated with cigarette smoking in non-diabetic healthy subjects. Diab Vasc Dis Res 2013; 10 (4) 380-382
  • 47 Smith DJ, Yerkovich ST, Towers MA, Carroll ML, Thomas R, Upham JW. Reduced soluble receptor for advanced glycation end-products in COPD. Eur Respir J 2011; 37 (3) 516-522
  • 48 Braquet P, Hosford D, Braquet M, Bourgain R, Bussolino F. Role of cytokines and platelet-activating factor in microvascular immune injury. Int Arch Allergy Appl Immunol 1989; 88 (1-2) 88-100
  • 49 Yuo A, Kitagawa S, Kasahara T, Matsushima K, Saito M, Takaku F. Stimulation and priming of human neutrophils by interleukin-8: cooperation with tumor necrosis factor and colony-stimulating factors. Blood 1991; 78 (10) 2708-2714
  • 50 Ellis TN, Beaman BL. Interferon-gamma activation of polymorphonuclear neutrophil function. Immunology 2004; 112 (1) 2-12
  • 51 Watson DA, Musher DM, Hamill RJ. Interferon-gamma and polymorphonuclear leukocytes. Ann Intern Med 1988; 109 (3) 250-251
  • 52 Steinberg D. Antioxidants and atherosclerosis. A current assessment. Circulation 1991; 84 (3) 1420-1425
  • 53 Prasad K. Textbook of Angiology. In: John B Chang, Earl R Olsen, Kailash Prasad, Bauer E Sumpio, eds. Pathophysiology of Atherosclerosis. New York, NY: Springer-Verlag; 2000: 85-105
  • 54 Martin A, Foxall T, Blumberg JB, Meydani M. Vitamin E inhibits low-density lipoprotein-induced adhesion of monocytes to human aortic endothelial cells in vitro. Arterioscler Thromb Vasc Biol 1997; 17 (3) 429-436
  • 55 Faruqi R, de la Motte C, DiCorleto PE. Alpha-tocopherol inhibits agonist-induced monocytic cell adhesion to cultured human endothelial cells. J Clin Invest 1994; 94 (2) 592-600
  • 56 Devaraj S, Li D, Jialal I. The effects of alpha tocopherol supplementation on monocyte function. Decreased lipid oxidation, interleukin 1 beta secretion, and monocyte adhesion to endothelium. J Clin Invest 1996; 98 (3) 756-763
  • 57 Keaney Jr JF, Gaziano JM, Xu A , et al. Low-dose alpha-tocopherol improves and high-dose alpha-tocopherol worsens endothelial vasodilator function in cholesterol-fed rabbits. J Clin Invest 1994; 93 (2) 844-851
  • 58 Nakamura K, Yamagishi S, Adachi H , et al. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 2007; 13 (3-4) 185-189
  • 59 Pullerits R, Brisslert M, Jonsson IM, Tarkowski A. Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1. Arthritis Rheum 2006; 54 (12) 3898-3907
  • 60 Fujisawa K, Katakami N, Kaneto H , et al. Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes. Atherosclerosis 2013; 227 (2) 425-428
  • 61 Tan KCB, Shiu SWM, Chow WS, Leng L, Bucala R, Betteridge DJ. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006; 49 (11) 2756-2762
  • 62 Challier M, Jacqueminet S, Benabdesselam O, Grimaldi A, Beaudeux JL. Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clin Chem 2005; 51 (9) 1749-1750
  • 63 Basta G, Leonardis D, Mallamaci F , et al. Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int 2010; 77 (3) 225-231
  • 64 Hammady MR, Khashali SEL, Halim HA, Rashed L, Hussein M. Soluble receptor for advanced glycation end products (sRAGE) in non-diabetic hemodialysis patients and chronic kidney disease. Med J Cairo Univ 2012; 80: 9-75
  • 65 Tan KC, Chow WS, Tam S, Bucala R, Betteridge J. Association between acute-phase reactants and advanced glycation end products in type 2 diabetes. Diabetes Care 2004; 27 (1) 223-228
  • 66 Berg TJ, Dahl-Jørgensen K, Torjesen PA, Hanssen KF. Increased serum levels of advanced glycation end products (AGEs) in children and adolescents with IDDM. Diabetes Care 1997; 20 (6) 1006-1008
  • 67 Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 1999; 22 (9) 1543-1548
  • 68 Raj DS, Choudhury D, Welbourne TC, Levi M. Advanced glycation end products: a Nephrologist's perspective. Am J Kidney Dis 2000; 35 (3) 365-380
  • 69 Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oreopoulos D, Diamandis EP. Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 1994; 46 (1) 216-222
  • 70 Prasad K. Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease states: Myth or reality. Int J Angiol 2014; 23: 11-16